Susan Tran

Nov 20, 2023 | cmaj.ca | Shohinee Sarma |Michael Fralick |Susan Tran

Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP1RA) is a weekly subcutaneous injection for adults with obesitySemaglutide was approved for adults with a body mass index (BMI) of 30 kg/m2 or greater, and those with a BMI of 27 kg/m2 or greater with 1 or more obesity-related comorbidities (e.g., hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea).